{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:57:44Z","timestamp":1780059464955,"version":"3.54.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sintilimab, a programmed death-1 (PD-1) inhibitor widely used in various malignancies, has demonstrated favorable antitumor efficacy and safety. However, severe immune-related cutaneous adverse events (irCAEs) such as toxic epidermal necrolysis (TEN) are rare but potentially fatal. Understanding their clinical characteristics, treatment strategies, and pathophysiological mechanisms is crucial for optimal management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a case of a patient with gastric carcinoma who developed delayed-onset TEN after receiving four cycles of neoadjuvant sintilimab combined with the SOX regimen (S-1 and oxaliplatin). The patient subsequently underwent radical gastrectomy, and postoperative pathology confirmed a complete pathological response. On the third postoperative day, the patient developed a scattered erythematous rash that began on the back and spread to the upper abdomen and upper and lower limbs, forming plaques. A dermatology consultation and clinical evaluation led to a diagnosis of immune-related TEN. The patient received systemic methylprednisolone and comprehensive supportive care, resulting in a gradual recovery of skin lesions, with no recurrence of TEN during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case suggests that sintilimab-induced TEN can occur as a delayed immune-mediated reaction, even after drug discontinuation. The potential mechanism of sintilimab-induced TEN may involve the excessive activation of cytotoxic T lymphocytes and dysregulated immune responses leading to keratinocyte apoptosis through Fas\/FasL and perforin\u2013granzyme pathways. Notably, the occurrence of irCAEs has been associated with favorable antitumor responses in some patients, reflecting strong immune activation. Prompt discontinuation of immunotherapy, early initiation of high-dose corticosteroids, and supportive measures remain the cornerstone of management. TNF-\u03b1 or JAK inhibitors may provide therapeutic benefit in refractory cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights a rare instance of delayed-onset TEN following sintilimab-based neoadjuvant therapy in gastric cancer, occurring shortly after surgical resection despite a complete pathological response. Early recognition and timely immunosuppressive treatment are essential for favorable outcomes. Further investigation into the mechanisms and predictive factors of PD-1 inhibitor\u2013induced TEN is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1752915","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:39:34Z","timestamp":1776832774000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Sintilimab-induced delayed-onset toxic epidermal necrolysis in a patient with gastric carcinoma: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Qiaoqiao","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shanghai Xuhui Central Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilong","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Xuhui Central Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Xuhui Central Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Xuhui Central Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Xuhui Central Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Xuhui Central Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Xuhui Central Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Xuhui Central Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Xuhui Central Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Xuhui Central Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"Ca-Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-023-01431-z","article-title":"SOX combined with sintilimab versus SOX alone in the perioperative management of locally advanced gastric cancer: a propensity score-matched analysis","volume":"26","author":"Huang","year":"2023","journal-title":"Gastric Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1414136","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0074","article-title":"Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review","volume":"14","author":"Yang","year":"2022","journal-title":"Immunotherapy-Uk"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.3003","article-title":"Cutaneous adverse events and cancer survival prognosis with immune checkpoint inhibitor treatment: a systematic review and meta-analysis","volume":"159","author":"Du","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/cancers16020340","article-title":"Incidence of cutaneous immune-related adverse events and outcomes in immune checkpoint inhibitor-containing regimens: a systematic review and meta-analysis","volume":"16","author":"Curkovic","year":"2024","journal-title":"Cancers"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17683","article-title":"Cutaneous side effects of PD-1 inhibitors: a single-center retrospective study","volume":"64","author":"Pozsgai","year":"2025","journal-title":"Int J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103376","article-title":"Cutaneous adverse events associated with immune checkpoint blockade: a systematic review and meta-analysis","volume":"163","author":"Han","year":"2021","journal-title":"Crit Rev Oncol Hemat"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21781","article-title":"Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients","volume":"187","author":"Nikolaou","year":"2022","journal-title":"Brit J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33765","article-title":"Characterizing immune checkpoint inhibitor-related cutaneous adverse reactions: a comprehensive analysis of FDA adverse event reporting system (FAERS) database","volume":"10","author":"Esen","year":"2024","journal-title":"Heliyon"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.14262","article-title":"Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: a case\/non-case analysis using the Food and Drug Administration Adverse Event Reporting System","volume":"65","author":"Godfrey","year":"2024","journal-title":"Australas J Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jaad.2013.05.003","article-title":"Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis","volume":"69","author":"Schwartz","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.autrev.2008.06.004","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Borchers","year":"2008","journal-title":"Autoimmun Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1065137","article-title":"Case report: toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.330","article-title":"TNF-alpha and IFN-gamma are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis","volume":"133","author":"Viard-Leveugle","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S401286","article-title":"Adalimumab for sintilimab-induced toxic epidermal necrolysis in a patient with metastatic gastric Malignancy: a case report and literature review","volume":"16","author":"Zhang","year":"2023","journal-title":"Clin Cosmet Inv Derm"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08061-0","article-title":"Spatial proteomics identifies JAKi as treatment for a lethal skin disease","volume":"635","author":"Nordmann","year":"2024","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1076473","article-title":"Selected cutaneous adverse events in patients treated with ICI monotherapy and combination therapy: a retrospective pharmacovigilance study and meta-analysis","volume":"14","author":"Lu","year":"2023","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100951","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database","volume":"37","author":"Zhu","year":"2021","journal-title":"Eclinicalmedicine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S491791","article-title":"Clinical features of Stevens-Johnson syndrome and toxic epidermal necrolysis induced by immune checkpoint inhibitor versus non-immune checkpoint inhibitor drugs in China: a cross-sectional study and literature review","volume":"17","author":"Qin","year":"2024","journal-title":"J Inflammation Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1563100","article-title":"Clinical features of nivolumab-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis: retrospective analysis based on case reports","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1707956","article-title":"Tislelizumab-associated toxic epidermal necrolysis in an esophageal cancer patient: a case report","volume":"16","author":"Jin","year":"2025","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.974376","article-title":"PD-1 inhibitor-based adverse events in solid tumors: a retrospective real-world study","volume":"13","author":"Huang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S353743","article-title":"Treatment of PD-1 inhibitor-associated toxic epidermal necrolysis: a case report and brief review","volume":"15","author":"Zhao","year":"2022","journal-title":"Oncotargets Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.989966","article-title":"Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: a case report","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.707967","article-title":"Case report: a case report and literature review on severe bullous skin reaction induced by anti-PD-1 immunotherapy in a cervical cancer patient","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"655732812","DOI":"10.1177\/03000605231173556","article-title":"A case of toxic epidermal necrolysis associated with lenvatinib and sintilimab therapy for intrahepatic cholangiocarcinoma","volume":"51","author":"Gong","year":"2023","journal-title":"J Int Med Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.912168","article-title":"Case report: sintilimab-induced Stevens-Johnson syndrome in a patient with advanced lung adenocarcinoma","volume":"13","author":"Li","year":"2023","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1752915\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:39:47Z","timestamp":1776832787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1752915\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":30,"alternative-id":["10.3389\/fonc.2026.1752915"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1752915","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1752915"}}